--- title: "史赛克在从网络攻击中恢复的过程中，第二季度的利润和收入均有所增加" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/294415083.md" description: "史赛克报告第二季度利润为 12.8 亿美元，收入增长至 65.9 亿美元，恢复了 3 月份网络攻击后的损失。调整后的每股收益为 3.69 美元，超出预期。公司缩小了全年指引，预计调整后的每股收益在 14.95 美元至 15.10 美元之间。尽管财务结果强劲，股价在盘后交易中下跌了 9.5%" datetime: "2026-07-30T20:53:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294415083.md) - [en](https://longbridge.com/en/news/294415083.md) - [zh-HK](https://longbridge.com/zh-HK/news/294415083.md) generator: "portal-rs" --- # 史赛克在从网络攻击中恢复的过程中，第二季度的利润和收入均有所增加 By Elias Schisgall Stryker reported a higher profit and revenue growth in the second quarter as the company recovers from a March cyberattack. The medical technology company on Thursday reported a profit of $1.28 billion, or $3.30 a share, compared with a profit of $884 million, or $2.29 a share, a year earlier. Stripping out certain one-time items, Stryker posted adjusted earnings of $3.69 a share. Analysts surveyed by FactSet were expecting $3.49 a share. Sales rose to $6.59 billion from $6.02 billion, beating analyst expectations for $6.58 billion. MedSurg and Neurotechnology sales rose 9.7%, while the orthopaedics unit reported 9.1% sales growth. Stryker also narrowed its full-year guidance, projecting adjusted earnings of between $14.95 and $15.10 a share, up from a previous low end of $14.90. It expects organic net sales growth between 8.3% and 9.3%, compared with a previous range of 8% to 9.5%. Analysts are expecting full-year adjusted earnings of $14.97 a share. The new sales guidance includes a "modestly positive pricing impact," the company said. Shares of Stryker fell 9.5% to $315.00 in after-hours trading on Thrusday. Chief Executive Kevin Lobo said that company has made "significant progress in our recovery" from the March cyberattack, which disrupted Stryker's Microsoft systems and impacted its first-quarter results. The Wall Street Journal has reported that the hackers behind the attack said they were retaliating against the U.S. on Iran's behalf. "As we have seen in the past, the resilience of our teams when faced with challenges was once again on display," Lobo said. "With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech." Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires July 30, 2026 16:46 ET (20:46 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相关股票 - [SYK.US](https://longbridge.com/zh-CN/quote/SYK.US.md) - [FDS.US](https://longbridge.com/zh-CN/quote/FDS.US.md) - [MSFT.US](https://longbridge.com/zh-CN/quote/MSFT.US.md) ## 相关资讯与研究 - [一周回顾 | 史赛克累跌 9.1%，多数机构给予买入](https://longbridge.com/zh-CN/news/298795326.md) - [史赛克｜8-K：2026 财年 Q2 营收 65.89 亿美元超过预期](https://longbridge.com/zh-CN/news/294410562.md) - [美股夜盘异动：史赛克夜盘跌 6.65%，业绩超预期却下调指引，市场信心受挫](https://longbridge.com/zh-CN/news/294437773.md) - [史赛克公司为副总裁兼公司控制员 Emily Kay Baculik 提交了 3 号表格](https://longbridge.com/zh-CN/news/298359712.md) - [BONESUPPORT 与史赛克合作在澳大利亚和新西兰进行产品分销](https://longbridge.com/zh-CN/news/298734332.md) --- > **免责声明: 本文仅供参考，不构成任何投资建议。**